75.2 F
Thursday, October 6, 2022

Miami-Based Clinical Trial Company First in U.S. to Run Human Trials for Optimized Form of LSD

Principal Investigator for the MM-120 trial is Dr. Rishi Kakar.

Segal Trials, a privately held network of clinical research sites throughout South
Florida, announced that its investigators and the site are the first in the United
States to conduct a large, randomized clinical trial to investigate MM-120 (LSD
D-tartrate), for the treatment of Generalized Anxiety Disorder (GAD).
Segal Trials’ investigators administered the first dose of MM-120 to a study
participant on August 24 at The Center for Psychedelic and Cannabis Research
in Miami.

Dr. Rishi Kakar, Medical Director and Chief Scientific Officer at Segal Trials,
serves as a Principal Investigator for the MM-120 trial, which is a randomized,
double- blind, parallel-group design study to evaluate the potential effectiveness
of MM-120 in patients with GAD.

“MindMed’s compound has the potential to change the way clinicians treat GAD,”
said Dr. Kakar. “Certainly, conducting the first trial of its kind in the nation puts
our companies at the forefront of psychedelic pharmacological research.”
Dr. Kakar and his team will conduct the trial at Segal’s Center for Psychedelic
and Cannabis Research, which was specifically built to create a structured
inpatient environment that ensures patient safety and comfort.

About Generalized Anxiety Disorder (GAD)
GAD is a chronic, often debilitating mental health disorder that affects
approximately 6% of U.S. adults in their lifetimes. Symptoms of GAD include
excessive anxiety and worry that persists for over six months, which can lead to
significant impairments in social, occupational, and other functioning, according
to the National Institute of Mental Health (NIMH).
While there is substantial diagnostic overlap between GAD, Major Depressive
Disorder (MDD) and other major mental health disorders, there has been very
little innovation focused on the treatment of GAD in the past several decades due
to the shift in focus from anxiety disorders like GAD toward depressive disorders
like MDD, driven by the marketing of serotonin reuptake inhibitors starting in the

About Segal Trials
Segal Trials, founded in 1998, is a privately held network of research sites
throughout South Florida conducting Phase I-IV research trials that have led to
54 FDA-approved medications and devices. The company’s trials focus on
psychiatry, neurology, addiction, insomnia, infectious diseases, vaccine
development, and women’s health; and it runs trials in outpatient, inpatient, PSG,
and residential care facility settings.

Segal Trials, founded in 1998, is a privately held network of five research sites
throughout South Florida conducting Phase I-IV research trials with a primary
emphasis on psychiatry, neurology, addiction, insomnia, general medicine,
healthy volunteers, infectious diseases, vaccines, and women’s health.
To date, Segal Trials has been an instrumental part in conducting studies
resulting in 48 medications and devices that are FDA approved and are changing
the quality of life for millions. In addition to conducting clinical trials, Segal Trials
also offers data management, bioanalytical lab analysis, medical writing, protocol
design and review, project management, budget development and clinical data
monitoring services through established vendor relationships and inhouse

Segal Trials is regarded as an innovator and a leader in the advancement of
medicine with a strong dedication to the community it serves by spreading
awareness about clinical trials as a potential care option. Segal Trials is affiliated
with Compass Health Systems, a behavioral health care group practice serving
the community since 1990.

Segal Trials additionally, partners with local South Florida Geriatric Residential
Care Facilities for inpatient research studies in neurology.

About MindMed
MindMed is a clinical stage biopharmaceutical company developing novel
products to treat brain health disorders, with a particular focus on psychiatry,
addiction, pain, and neurology. The company is developing a pipeline of
innovative drug candidates, with and without acute perceptual effects, targeting
the serotonin, dopamine, and acetylcholine systems. MindMed trades on
NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under
the symbol MMED.

Connect To Your Customers & Grow Your Business

Click Here


Related Articles

- Advertisement -

Latest Articles